Clinical Cancer Research Meeting Calendar Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Clinical Cancer Research 13, 2890, May 15, 2007. doi: 10.1158/1078-0432.CCR-06-3043
© 2007 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Massarelli, E.
Right arrow Articles by Wistuba, I. I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Massarelli, E.
Right arrow Articles by Wistuba, I. I.

Imaging, Diagnosis, Prognosis

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

Erminia Massarelli1, Marileila Varella-Garcia4, Ximing Tang1, Ana C. Xavier4, Natalie C. Ozburn1, Diane D. Liu2, Benjamin N. Bekele2, Roy S. Herbst1 and Ignacio I. Wistuba1,3

Authors' Affiliations: Departments of 1 Thoracic/Head and Neck Medical Oncology, 2 Biostatistics and Applied Mathematics, and 3 Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas and 4 University of Colorado Health Sciences Center, Cancer Center, Aurora, Colorado

Requests for reprints: Ignacio I. Wistuba, Department of Pathology, M. D. Anderson Cancer Center, Unit 85, 1515 Holcombe Boulevard, Houston, TX 77030-4009. Phone: 713-563-9184; Fax: 713-563-1848; E-mail: iiwistuba{at}mdanderson.org.

Purpose: EGFR gene mutations and increased EGFR copy number have been associated with favorable response to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) in patients with non–small-cell lung cancer (NSCLC). In contrast, KRAS mutation has been shown to predict poor response to such therapy. We tested the utility of combinations of these three markers in predicting response and survival in patients with NSCLC treated with EGFR-TKIs.

Experimental Design: Patients with advanced NSCLC treated with EGFR-TKI with available archival tissue specimens were included. EGFR and KRAS mutations were analyzed using PCR-based sequencing. EGFR copy number was analyzed using fluorescence in situ hybridization.

Results: The study included 73 patients, 59 of whom had all three potential markers successfully analyzed. EGFR mutation was detected in 7 of 71 patients (9.8%), increased EGFR copy number in 32 of 59 (54.2%), and KRAS mutation in 16 of 70 (22.8%). EGFR mutation (P < 0.0001) but not increased EGFR copy number (P = 0.48) correlated with favorable response. No survival benefit was detected in patients with either of these features. KRAS mutation correlated with progressive disease (P = 0.04) and shorter median time to progression (P = 0.0025) but not with survival. Patients with both EGFR mutation and increased EGFR copy number had a >99.7% chance of objective response, whereas patients with KRAS mutation with or without increased EGFR copy number had a >96.5% chance of disease progression.

Conclusion: KRAS mutation should be included as indicator of resistance in the panel of markers used to predict response to EGFR-TKIs in NSCLC.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
J. M. Brannan, W. Dong, L. Prudkin, C. Behrens, R. Lotan, B. N. Bekele, I. Wistuba, and F. M. Johnson
Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-Small Cell Lung Cancer
Clin. Cancer Res., July 1, 2009; 15(13): 4423 - 4430.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
S. Lorenzen, T. Schuster, R. Porschen, S.-E. Al-Batran, R. Hofheinz, P. Thuss-Patience, M. Moehler, P. Grabowski, D. Arnold, T. Greten, et al.
Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie
Ann. Onc., June 23, 2009; (2009) mdp069v1.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Bao, C.-J. Lai, H. Qu, D. Wang, L. Yin, B. Zifcak, R. Atoyan, J. Wang, M. Samson, J. Forrester, et al.
CUDC-305, a Novel Synthetic HSP90 Inhibitor with Unique Pharmacologic Properties for Cancer Therapy
Clin. Cancer Res., June 15, 2009; 15(12): 4046 - 4057.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
O. B. Rickman, P. K. Vohra, B. Sanyal, J. A. Vrana, M.-C. Aubry, D. A. Wigle, and C. F. Thomas Jr.
Analysis of ErbB Receptors in Pulmonary Carcinoid Tumors
Clin. Cancer Res., May 15, 2009; 15(10): 3315 - 3324.
[Abstract] [Full Text] [PDF]

Home page
 Proc Am Thorac SocHome page
G. J. Riely, J. Marks, and W. Pao
KRAS Mutations in Non-Small Cell Lung Cancer
Proceedings of the ATS, April 15, 2009; 6(2): 201 - 205.
[Abstract] [Full Text] [PDF]

Home page
 Am J Clin PatholHome page
G. Sartori, A. Cavazza, A. Sgambato, A. Marchioni, F. Barbieri, L. Longo, M. Bavieri, B. Murer, E. Meschiari, S. Tamberi, et al.
EGFR and K-ras Mutations Along the Spectrum of Pulmonary Epithelial Tumors of the Lung and Elaboration of a Combined Clinicopathologic and Molecular Scoring System to Predict Clinical Responsiveness to EGFR Inhibitors
Am J Clin Pathol, April 1, 2009; 131(4): 478 - 489.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
J. R. Grandis and A. Argiris
Targeting Angiogenesis from Premalignancy to Metastases
Cancer Prevention Research, April 1, 2009; 2(4): 291 - 294.
[Full Text] [PDF]

Home page
 JCOHome page
A. N. Hughes, M. E.R. O'Brien, W. J. Petty, J. B. Chick, E. Rankin, P. J. Woll, D. Dunlop, M. Nicolson, R. Boinpally, J. Wolf, et al.
Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
J. Clin. Oncol., March 10, 2009; 27(8): 1220 - 1226.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
P. Laurent-Puig, A. Lievre, and H. Blons
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Clin. Cancer Res., February 15, 2009; 15(4): 1133 - 1139.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Cappuzzo, P. A. Janne, M. Skokan, G. Finocchiaro, E. Rossi, C. Ligorio, P. A. Zucali, L. Terracciano, L. Toschi, M. Roncalli, et al.
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients
Ann. Onc., February 1, 2009; 20(2): 298 - 304.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. T. Ihle, R. Lemos Jr., P. Wipf, A. Yacoub, C. Mitchell, D. Siwak, G. B. Mills, P. Dent, D. L. Kirkpatrick, and G. Powis
Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance
Cancer Res., January 1, 2009; 69(1): 143 - 150.
[Abstract] [Full Text] [PDF]

Home page
 Am Soc Clin Oncol Ed BookHome page
M. A. Socinski
What Guides Decisions about the Use of Epidermal Growth Factor Receptor Antibody or Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer?
ASCO Educational Book, January 1, 2009; 2009(1): 436 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Z. S. Boyd, Q. J. Wu, C. O'Brien, J. Spoerke, H. Savage, P. J. Fielder, L. Amler, Y. Yan, and M. R. Lackner
Proteomic analysis of breast cancer molecular subtypes and biomarkers of response to targeted kinase inhibitors using reverse-phase protein microarrays
Mol. Cancer Ther., December 1, 2008; 7(12): 3695 - 3706.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. A. Pratilas, A. J. Hanrahan, E. Halilovic, Y. Persaud, J. Soh, D. Chitale, H. Shigematsu, H. Yamamoto, A. Sawai, M. Janakiraman, et al.
Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer
Cancer Res., November 15, 2008; 68(22): 9375 - 9383.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. J. Riely and M. Ladanyi
KRAS Mutations: An Old Oncogene Becomes a New Predictive Biomarker
J. Mol. Diagn., November 1, 2008; 10(6): 493 - 495.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. S. Karapetis, S. Khambata-Ford, D. J. Jonker, C. J. O'Callaghan, D. Tu, N. C. Tebbutt, R. J. Simes, H. Chalchal, J. D. Shapiro, S. Robitaille, et al.
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
N. Engl. J. Med., October 23, 2008; 359(17): 1757 - 1765.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Fichtner, J. Rolff, R. Soong, J. Hoffmann, S. Hammer, A. Sommer, M. Becker, and J. Merk
Establishment of Patient-Derived Non-Small Cell Lung Cancer Xenografts as Models for the Identification of Predictive Biomarkers
Clin. Cancer Res., October 15, 2008; 14(20): 6456 - 6468.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. Kelly, M. W. Redman, and D. R. Gandara
In Reply
J. Clin. Oncol., October 10, 2008; 26(29): 4850 - 4851.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
N. Personeni, S. Fieuws, H. Piessevaux, G. De Hertogh, J. De Schutter, B. Biesmans, W. De Roock, A. Capoen, M. Debiec-Rychter, J.-L. Van Laethem, et al.
Clinical Usefulness of EGFR Gene Copy Number as a Predictive Marker in Colorectal Cancer Patients Treated with Cetuximab: A Fluorescent In situ Hybridization Study
Clin. Cancer Res., September 15, 2008; 14(18): 5869 - 5876.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C.-Q. Zhu, G. da Cunha Santos, K. Ding, A. Sakurada, J.-C. Cutz, N. Liu, T. Zhang, P. Marrano, M. Whitehead, J. A. Squire, et al.
Role of KRAS and EGFR As Biomarkers of Response to Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21
J. Clin. Oncol., September 10, 2008; 26(26): 4268 - 4275.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Morgan, L. A. Parsels, L. E. Kollar, D. P. Normolle, J. Maybaum, and T. S. Lawrence
The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer
Clin. Cancer Res., August 15, 2008; 14(16): 5142 - 5149.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
X. Tang, M. Varella-Garcia, A. C. Xavier, E. Massarelli, N. Ozburn, C. Moran, and I. I. Wistuba
Epidermal Growth Factor Receptor Abnormalities in the Pathogenesis and Progression of Lung Adenocarcinomas
Cancer Prevention Research, August 1, 2008; 1(3): 192 - 200.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. R. Hirsch, R. S. Herbst, C. Olsen, K. Chansky, J. Crowley, K. Kelly, W. A. Franklin, P. A. Bunn Jr, M. Varella-Garcia, and D. R. Gandara
Increased EGFR Gene Copy Number Detected by Fluorescent In Situ Hybridization Predicts Outcome in Non-Small-Cell Lung Cancer Patients Treated With Cetuximab and Chemotherapy
J. Clin. Oncol., July 10, 2008; 26(20): 3351 - 3357.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. L. Keedy, C. L. Arteaga, and D. H. Johnson
Does Gefitinib Shorten Lung Cancer Survival? Chaos Redux
J. Clin. Oncol., May 20, 2008; 26(15): 2428 - 2430.
[Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
K. Liby, C. C. Black, D. B. Royce, C. R. Williams, R. Risingsong, M. M. Yore, X. Liu, T. Honda, G. W. Gribble, W. W. Lamph, et al.
The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis
Mol. Cancer Ther., May 1, 2008; 7(5): 1251 - 1257.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
A. R. Li, D. Chitale, G. J. Riely, W. Pao, V. A. Miller, M. F. Zakowski, V. Rusch, M. G. Kris, and M. Ladanyi
EGFR Mutations in Lung Adenocarcinomas: Clinical Testing Experience and Relationship to EGFR Gene Copy Number and Immunohistochemical Expression
J. Mol. Diagn., May 1, 2008; 10(3): 242 - 248.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Baselga and N. Rosen
Determinants of RASistance to Anti-Epidermal Growth Factor Receptor Agents
J. Clin. Oncol., April 1, 2008; 26(10): 1582 - 1584.
[Full Text] [PDF]

Home page
 JCOHome page
R. G. Amado, M. Wolf, M. Peeters, E. Van Cutsem, S. Siena, D. J. Freeman, T. Juan, R. Sikorski, S. Suggs, R. Radinsky, et al.
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
J. Clin. Oncol., April 1, 2008; 26(10): 1626 - 1634.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F. Cappuzzo, G. Finocchiaro, E. Rossi, P.A. Janne, C. Carnaghi, C. Calandri, K. Bencardino, C. Ligorio, F. Ciardiello, T. Pressiani, et al.
EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients
Ann. Onc., April 1, 2008; 19(4): 717 - 723.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Ciardiello and G. Tortora
EGFR Antagonists in Cancer Treatment
N. Engl. J. Med., March 13, 2008; 358(11): 1160 - 1174.
[Full Text] [PDF]

Home page
 JCOHome page
N. Normanno and A. De Luca
Erlotinib in Pancreatic Cancer: Are Tumor Cells the (only) Target?
J. Clin. Oncol., December 20, 2007; 25(36): 5836 - 5837.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2007 by the American Association for Cancer Research.